Hewlings Susan, Kalman Douglas S
Department of Nutrition, Central Michigan University, Mount Pleasant, MI, United States.
Nova Southeastern University, Health Professionals Division, Exercise Science, Davie, FL, United States.
JMIR Res Protoc. 2018 Nov 29;7(11):e11139. doi: 10.2196/11139.
The sulfur-containing compound methylsulfonylmethane (MSM) has been used as a dietary supplement for a variety of reported health benefits. Clinical observations and case studies have indicated that MSM may help alleviate allergic rhinitis; however, this effect has not been evaluated under controlled conditions.
This study aimed to determine the effects of MSM consumption on allergic rhinitis symptoms after provocation with a standardized allergen.
We recruited healthy participants with a history of allergic nasal congestion to participate in a randomized, double-blind, adaptive-design study. Participants were administered a standardized allergen in clinic to determine the presence or absence of an allergic response. Participant responses were recorded using a recognized measure of nasal patency, peak nasal inspiratory flow (PNIF), and by a visual analog scale to score the severity of their allergy-related nasal symptoms. After we collected baseline nasal responses to allergen, followed by a 1-week washout period, participants returned to the clinic and were exposed to allergen after taking an acute high dose of 12 g of MSM. We then randomly assigned participants to a lower dose of MSM (1 g, 3 g, or 6 g), which they consumed once a day for 14 days. Participants returned to the clinic for repeat assessments while again taking their assigned daily dose of MSM.
All MSM treatment courses significantly reduced visual analog scale average nasal symptoms in a longitudinal comparison across all participants, with low-dose treatments decreasing symptoms by 53.72% (P=.001), and an acute 12-g dose decreasing symptoms by 22.49% (P=.03). Although the acute dose of MSM did not yield significant changes in nasal patency, low "everyday" doses significantly relieved nasal obstruction as indicated by a 17.32% (P=.02) increase in PNIF across all participants. The most effective dose across all measurements was daily consumption of 3 g of MSM, which significantly decreased all nasal symptoms (nasal obstruction, rhinorrhea, watery or itchy eyes and nose, and sneezing) and further was found to significantly (P=.01) increase PNIF.
The MSM study product provided significant relief of allergic rhinitis symptoms and objective nasal obstruction measurements without the occurrence of adverse events. Oral consumption of the study product may reduce the symptoms and onset of allergic rhinitis without the side effects associated with standard-care medication.
ClinicalTrials.gov NCT02342483; https://clinicaltrials.gov/ct2/show/NCT02342483 (Archived by WebCite at http://www.webcitation.org/73vLKNvAp).
含硫化合物二甲基砜（MSM）已被用作膳食补充剂，据称有多种健康益处。临床观察和病例研究表明，MSM可能有助于缓解过敏性鼻炎；然而，这种效果尚未在对照条件下进行评估。
本研究旨在确定摄入MSM对标准化变应原激发后过敏性鼻炎症状的影响。
我们招募了有过敏性鼻充血病史的健康参与者，参与一项随机、双盲、适应性设计研究。参与者在诊所接受标准化变应原检测，以确定是否存在过敏反应。使用公认的鼻通畅度测量方法——峰值鼻吸气流量（PNIF），并通过视觉模拟量表记录参与者的反应，以评估其过敏相关鼻部症状的严重程度。在收集了对变应原的基线鼻部反应后，经过1周的洗脱期，参与者返回诊所，在服用12克MSM急性高剂量后接触变应原。然后，我们将参与者随机分配至较低剂量的MSM组（1克、3克或6克），他们每天服用一次，持续14天。参与者再次返回诊所进行重复评估，同时继续服用分配的每日剂量的MSM。
在对所有参与者的纵向比较中，所有MSM治疗疗程均显著降低了视觉模拟量表平均鼻部症状，低剂量治疗使症状减轻了53.72%（P = 0.001），急性12克剂量使症状减轻了22.49%（P = 0.03）。虽然MSM的急性剂量未使鼻通畅度产生显著变化，但低“日常”剂量显著缓解了鼻塞，所有参与者的PNIF增加了17.32%（P = 0.02）。所有测量中最有效的剂量是每天服用3克MSM，这显著减轻了所有鼻部症状（鼻塞、流涕、眼睛和鼻子水汪汪或发痒、打喷嚏），并且进一步发现显著（P = 0.01）增加了PNIF。
MSM研究产品显著缓解了过敏性鼻炎症状，并改善了客观的鼻塞测量结果，且未发生不良事件。口服该研究产品可能减轻过敏性鼻炎的症状和发作，而无标准护理药物相关的副作用。
ClinicalTrials.gov NCT02342483；https://clinicaltrials.gov/ct2/show/NCT02342483（由WebCite存档于http://www.webcitation.org/73vLKNvAp）。
